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1. Introduction
   Snake venoms have the highest toxicity potential that makes 
them an attractive option in the development of anticancer agents. 
Evolution of modern high throughput screening systems has helped 
to recognize and extract new therapeutic substances from biotoxins 
such as venoms of several snakes that show promising potential to 
combat cancer. Growing understanding of molecular mechanism is 
also contributing in this direction[1].
   Snake venom is a complex mixture of enzymes, peptides, 
carbohydrates, minerals and proteins of low molecular mass with 
specific chemical and biological activities[2,3]. Components of snake 
venoms can be used in the treatment of cancer, arthritis, thrombosis, 
multiple sclerosis, pain, neuromuscular disorders, blood and 
cardiovascular disorders, infections and inflammatory diseases[1-3].
Snake venom contains cytotoxins, cardiotoxins, hemotoxins, 
neurotoxins, nerve growth factor, inorganic cations like zinc, 
calcium, potassium, sodium and magnesium, etc. Phospholipase 
A2, ancrod, cobra venom factor, peptides, cytotoxins CT1, CT2 
and CT3, crotoxin, L-amino acid oxidases (LAAOs), lectins, 
metalloproteinases, disintegrins, serinoproteases, hyaluronidase, 
cholinesterases, salmosin, cathelicidin-BF, aggretin, obtustatin, 
rhodostomin, albolabrin, colombistatin, saxatilin and lebecetin are 
some of the components isolated from various snake venoms, which 
show promising applications in management of various human 
cancers. Several researches have been conducted on actions of snake 
venoms on tumor cell cultures and some of them are in phase I and 
phase II clinical trials[3-6].
   Disintegrins, like contortrostatin isolated from Agkistrodon 
contortrix venom prevents cells from adhering together and inhibits 
their interaction with surrounding tissue, resulting in decreased 
cell motility and invasiveness[1]. Cytotoxic effect of snake venom 
has potential to directly destroy tumor cells. Fibrin deposition 
around tumor could form a protective barrier, but also prevent 
tumor progression. Also fibrin deposits formed by metastatic tumor 
cells may help disseminating these tumor cells. Snake venom 
containing ancrod, a polypeptide can produce defibrination and 
decrease spread of some tumors[1,3,4]. C-type lectins inhibit integrin-
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dependent proliferation, migration, invasion, and angiogenesis. 
C-type lectins have been isolated from Macrovipera lebetina snake 
venom. Secreted phospholipases A2 (sPLA2) isolated from Cerastes 
cerastes and Macrovipera lebetina have promising antitumor and 
antiangiogenic properties since they act specifically on integrins 
α5β1 andααβ[7]. Also sPLA2 from Daboia russelii siamensis venom 
shows cytotoxic effect and inhibits cell migration in human skin 
melanoma cells. It also reduces tumor lung colonization of B16F10 
melanoma cells in BALB/c mice. sPLA2 has anticoagulant properties 
which may prevent recurrent thrombosis, which is the second most 
common cause of death in cancer patients[8].
2. Snake venom components
   Snake venom containing cystatin decreases tumor invasion and 
metastasis. Snake venom components can be specifically directed 
to cancer cells by combining the components with nanoparticles[5]. 
Cobra venom factor is an important factor for the synthesis of 
immunoconjugates, which are more specific towards carcinoma 
cells[3]. Cobra venom in very minute doses has powerful analgesic 
activity than morphine and can reduce intractable pain associated 
with cancer[1,2]. The enzyme LAAOs isolated from snake venoms 
induce apoptosis, alterations in cell cycle processes and cytotoxicity 
and have promising potentials in development of new antitumor 
agents[9,10]. Production of hydrogen peroxide during enzymatic 
reaction, caspases activation and interaction of LAAOs with 
membrane receptors are some of the possible mechanisms behind 
the actions of snake venom LAAOs[10].
   Snake venom components basically inhibit cell proliferation 
and promote cell death. Mechanisms of action include: increasing 
calcium ion influx, inducing cytochrome C release, increasing 
or decreasing the expression of proteins that control cell cycle, 
inflicting cell membrane damage, anti-platelet action preventing 
fibrin formation, preventing thrombin induced metastasis, inducing 
cancer cell apoptosis thereby controlling tumor size, direct toxicity 
and free radical generation, inhibiting nucleic acid synthesis thereby 
suppressing cell proliferation, decreasing the expression and activity 
of matrix metalloproteinases, inhibiting integrins thereby preventing 
migration and invasion of cancer cells, and antiangiogenesis. 
Cytotoxicity of snake venoms is related to alterations in cellular 
metabolism with a major effect on tumor cells when compared with 
normal cells[3-5].
3. Conclusions
   Venoms of Bothrops newweidii, Indian cobra Naja Naja, Naja 
nigricollis, Naja naja atra, Bothrops Leucurus, Opiophagus Hannah, 
Bothrops jararacussu, Naja Kaouthia, Okinawa Habu, Lapemis 
curtus, Daboia russelli russelli, Walterinessia aegyptia, Crotalus 
durissus terrificus, Agkistrodon acutus, Macrovipera lebentina, 
Bungarus multicinctus, Bungarus fasciatus, Laticauda semifasciata 
and Agkistrodon rhodostoma are of potential use in research directed 
towards management of cancer[1-6].
   Tagging gold nanoparticles with snake venom components has 
been found to increase their uptake by tumor cells[11]. Also silica 
nanoparticles tagged with snake venom components are observed 
to act specifically on tumor cells without affecting normal cells[12]. 
Novel snake venom delivery system with clinical applications to 
suppress tumors such as intravenous liposomal delivery, recombinant 
adenovirus carrying snake venom cystatin gene has been described 
in the literature[6]. Innovative research is required to discover novel, 
effective therapeutic anticancer agents from snake venoms in oral 
cancer patients. This promising area of research may bring hope, 
smile, comfort and cure to these group of cancer patients.
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